Specifically, a combination of nivolumab and ipilimumab [an anti-programmed cell death receptor-1 (PD-1) and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibodies] is recommended by international guidelines for intermediate- and poor-risk patients (1–3) according to the International Metastatic RCC Database Consortium (IMDC) criteria (4) (web calculator available at https://www.imdconline.com). This evidence concerns the gene CTLA4 and renal cell carcinoma.